Yahoo Finance Today's Research Reports on Stocks to Watch: Cytori Therapeutics and Novavax
NEW YORK, NY / ACCESSWIRE / July 25, 2017 / Cytori Therapeutics saw its shares crushed on Monday, with the stock losing 56% at the close. Investors were disappointed with the company's preliminary data from its pivotol STAR trial of HabeoTM Cell Therapy to treat scleroderma. Novavax shares saw a lot of activity yesterday as traders are anxiously awaiting the company's clinical update on its high-value respiratory syncytial virus (RSV) vaccine program.
RDI Initiates Coverage on:
Cytori Therapeutics, Inc.
https://ub.rdinvesting.com/news/?ticker=CYTX
Novavax, Inc.
https://ub.rdinvesting.com/news/?ticker=NVAX
Cytori Therapeutics, Inc. shares closed down over 56% on Monday and even hit a new low of $0.41. The stock saw staggering trading volume compared to usual with nearly 7.5 million shares traded compared to an average of around 700,000. The big drop came after the company announced top-line preliminary data from its pivotal STAR trial of HabeoTM Cell Therapy in patients that have scleroderma. Despite reporting clinically meaningful efficacy in the primary and secondary endpoints of both hand function and functional disability related to scleroderma, the primary endpoint, Cochin Hand Function Score (CHFS) was not achieved. Statistical significance was not achieved in primary or secondary efficacy endpoints. CEO Marc H. Hedrick commented, "We are disappointed that the study missed the primary and secondary endpoints. However, we are very encouraged by the trends toward improved hand function and scleroderma-related health status in patients with diffuse cutaneous scleroderma."
Access RDI's Cytori Therapeutics, Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=CYTX
Novavax, Inc. shares closed up 2.03% on nearly 35 million shares traded yesterday. The clinical-stage vaccine maker saw gains as high as 18% in yesterday's trading session before ending the day with a modest 2% gain. The big jump was mainly due to traders anxiously awaiting the company's clinical update on its high-value respiratory syncytial virus (RSV) vaccine program. There was no big news, however, the company did announce though that it would begin another mid-stage trial in older adults next year. Many investors had hoped to hear that there would be a pivotal-stage trial near. Despite ending the day with a 2% gain, the stock collapsed in after-hours trading with shares down 19.21%. The company forgoing a pivotal stage trial means there would be delays in the possibility of a regulatory filing for this indication.
Access RDI's Novavax, Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=NVAX
Our Actionable Research on Cytori Therapeutics, Inc. (NASDAQ: CYTX) and Novavax, Inc. (NASDAQ: NVAX) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer or a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
